MX2021003188A - Composiciones y métodos para la manufactura de vectores de terapia génica. - Google Patents

Composiciones y métodos para la manufactura de vectores de terapia génica.

Info

Publication number
MX2021003188A
MX2021003188A MX2021003188A MX2021003188A MX2021003188A MX 2021003188 A MX2021003188 A MX 2021003188A MX 2021003188 A MX2021003188 A MX 2021003188A MX 2021003188 A MX2021003188 A MX 2021003188A MX 2021003188 A MX2021003188 A MX 2021003188A
Authority
MX
Mexico
Prior art keywords
methods
compositions
gene therapy
therapy vectors
manufacturing gene
Prior art date
Application number
MX2021003188A
Other languages
English (en)
Inventor
Richard Truran
Julian Hanak
Original Assignee
Nightstarx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nightstarx Ltd filed Critical Nightstarx Ltd
Publication of MX2021003188A publication Critical patent/MX2021003188A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/08—Hollow fibre membranes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen métodos para la producción y/o purificación de una partícula de AAV recombinante (rAAV) a partir de un cultivo de células hospedadoras de mamífero.
MX2021003188A 2018-09-21 2019-09-23 Composiciones y métodos para la manufactura de vectores de terapia génica. MX2021003188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862734505P 2018-09-21 2018-09-21
PCT/US2019/052501 WO2020061581A1 (en) 2018-09-21 2019-09-23 Compositions and methods for manufacturing gene therapy vectors

Publications (1)

Publication Number Publication Date
MX2021003188A true MX2021003188A (es) 2021-07-16

Family

ID=69887990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003188A MX2021003188A (es) 2018-09-21 2019-09-23 Composiciones y métodos para la manufactura de vectores de terapia génica.

Country Status (12)

Country Link
US (1) US20210355503A1 (es)
EP (1) EP3853357A4 (es)
JP (1) JP2022501037A (es)
KR (1) KR20210093862A (es)
CN (1) CN113227362A (es)
AU (1) AU2019344073A1 (es)
BR (1) BR112021005110A2 (es)
CA (1) CA3112824A1 (es)
EA (1) EA202190512A1 (es)
IL (1) IL281586A (es)
MX (1) MX2021003188A (es)
WO (1) WO2020061581A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206103A (zh) * 2019-01-22 2022-03-18 蓝鸟生物公司 用于制造病毒载体的方法和系统
IL296258A (en) * 2020-03-16 2022-11-01 Ultragenyx Pharmaceutical Inc Methods for increasing the output of recombinant adeno-associated virus
IL302608A (en) * 2020-11-03 2023-07-01 Pfizer Methods for producing AAV vectors using ion exchange chromatography
GB202104611D0 (en) * 2021-03-31 2021-05-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
EP4355887A2 (en) * 2021-06-17 2024-04-24 Meiragtx UK II Limited Aav manufacturing methods
WO2022272296A2 (en) * 2021-06-25 2022-12-29 Homology Medicines, Inc. Adeno-associated virus packaging systems
GB202117844D0 (en) * 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20230323395A1 (en) * 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
WO2023139224A1 (en) * 2022-01-20 2023-07-27 Sartorius Xell GmbH METHOD FOR THE DETECTION AND QUANTIFICATION OF ADENO-ASSOCIATED VIRUSES (AAVs) USING AN AFFINITY MATRIX
WO2024011203A2 (en) * 2022-07-07 2024-01-11 Intergalactic Therapeutics, Inc. Ocular vectors and uses thereof
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles
WO2024102961A1 (en) * 2022-11-11 2024-05-16 Eli Lilly And Company Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077531C (en) * 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors
US11098286B2 (en) * 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
GB201704192D0 (en) * 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa

Also Published As

Publication number Publication date
KR20210093862A (ko) 2021-07-28
CA3112824A1 (en) 2020-03-26
US20210355503A1 (en) 2021-11-18
WO2020061581A1 (en) 2020-03-26
EP3853357A4 (en) 2022-11-02
IL281586A (en) 2021-05-31
BR112021005110A2 (pt) 2021-06-15
JP2022501037A (ja) 2022-01-06
AU2019344073A1 (en) 2021-05-06
EP3853357A1 (en) 2021-07-28
EA202190512A1 (ru) 2021-11-17
CN113227362A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
MX2021003188A (es) Composiciones y métodos para la manufactura de vectores de terapia génica.
PH12018501168A1 (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
PH12017501836A1 (en) Production of oversized adeno-associated vectors
PH12020500465A1 (en) Modified closed-ended dna (cedna)
CL2018000170A1 (es) Vectores de aav para la terapia génica de la retina y el snc (divisional de solicitud 201602713)
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
MX2018012376A (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
WO2015200920A8 (en) Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
MX2021013380A (es) Proteinas policlonales recombinantes y metodos de uso de las mismas.
PH12020551642A1 (en) Aav compositions, methods of making and methods of use
MX2020005282A (es) Vector para la produccion de particulas aav.
WO2020079034A3 (en) Intein proteins and uses thereof
MX2019008105A (es) Virus.
WO2021084277A3 (en) Transcription regulatory elements
WO2019121961A3 (en) Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
EP4073231A4 (en) RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND METHODS OF PRODUCTION
EP3878513A4 (en) GENE THERAPY USING SINGLE AAV VECTOR GENOEDITTING
MX2021011741A (es) Metodos para la fabricacion de vectores virales recombinantes.
MX2020002809A (es) Genes rep de aav inducibles.
MX2020002148A (es) Vectores adenoasociados recombinantes.
WO2017058884A3 (en) Modified bacterial protein expression system
WO2019074292A3 (ko) 고발현 및 고기능성 목적 단백질의 생산을 위한 발현 카세트 및 이의 이용
EP3956459A4 (en) NONVIRAL MODIFICATION OF T LYMPHOCYTE GENE EXPRESSION
MX2021005435A (es) Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2).
MX2018004188A (es) Composiciones y metodos que comprenden el uso de enzimas alfa-glucanotransferasas de exiguobacterium acetylicum y bacillus coagulans.